Jade Biosciences UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. We will keep us on schedule. All right. I get to say good afternoon. It is 12:00. Thank you very much for being with us here at the UBS Biopharma Conference. I am Michael Yee, Senior Biotechnology and Pharma Analyst here at UBS, and very excited to have Jade Biosciences up here with us. That includes the CEO, Tom Frohlich, and President of Research and Development, Dr. Andrew King. Thank you guys for being here. A lot going on in IgAN, and so I would love to turn it over to Tom just briefly. You could give us an introduction to Jade Biosciences. You have a potential best-in-class APRIL inhibitor for the treatment of IgAN. There are a lot of competitors in this space.
A lot of people have been listening to Vertex and other companies here, so I would love for you to give us an introduction to your company and why you think you have potential best-in-class product in IgAN.
Absolutely, and thanks for hosting.
And other products too. Yeah.
Thanks for hosting us and the whole UBS team. It's great to be here in London. We're really excited by our entire pipeline at Jade. We're a company developing best-in-class assets across a number of different autoimmune disorders. As Mike pointed out, our lead program is JADE101, which is a selective anti-APRIL inhibitor. IgAN, we believe, is a tremendously large commercial opportunity. We believe in the U.S. it's a $20 billion opportunity alone. We do believe that the selective anti-APRILs are going to be the dominant class because they have the potential to be disease modifying and have a very good tolerability profile.
With JADE101, we think there's a straight line to a best-in-class profile because of the increased potency to capture the full efficacy available to the mechanism, but also the extended dosing, which will allow for Q12-week dosing, which for patients who are diagnosed in their 20s and 30s and need lifelong therapy to be able to control their disease with only four injections a year, we think will be a really big advantage. We're currently in a phase II trial, moving very quickly towards a data readout in Q2 2027. So a big meaningful event for us with 101 next year. Also, we're not waiting for that data. We have so much conviction in this mechanism and the data from our phase I trial that we're aiming to initiate a phase III trial actually this quarter. So moving extremely quickly. Yeah.
I'll repeat that again. Initiating plans to start the phase III, and the phase II data hasn't even read out.
Yeah, correct. Just because there's so much conviction with that translatability of the healthy volunteer data into what we anticipate to see in patients. So that's 101. Most of the focus of our company is moving that forward. We're not just a single asset company. We also have JADE201, which is a BAFF receptor program, a really broad B-cell depleter, which we think has TCE-like efficacy in terms of B-cell depletion, but doesn't have some of that baggage associated with the cytokine release syndrome that you do see with TCEs. We believe with this mechanism, we can apply it to a number of different autoimmune diseases. We're currently in a phase I rheumatoid arthritis study and aim to read out that data next year in 2027.
At that point, we will provide more information on how we are planning to progress that trial across a number of different indications as well.
Talk about that one. Then we have a third program.
Sorry to take up a lot of time with the intro here, which is JADE301, which is targeting interferon beta. That is initially going to be developed in dermatomyositis, which is a very severe neuromuscular and skin disorder, as the name would suggest. We are following the footsteps of a program at Pfizer called dazukibart, which is also an interferon beta, showed extremely positive phase II data, showing really good activity on the neuromuscular and skin components. So we believe we have a possibility of having a best-in-disease class. The big liability with dazukibart, it has very low bioavailability, so it has to be dosed IV. With JADE301, the way it is designed, we believe it will be a sub-Q dosing with very convenient dosing as well. So capture all the efficacy for that mechanism, but do it in a much more convenient way for patient.
We are aiming to have data on a healthy volunteer study for that program in the second half of next year to enable us to move quickly into patients.
So lots of activity. If I could do that in reverse.
People have heard about some of the data that Pfizer has, that Pfizer has moved into a phase III. It is sort of a first-generation drug. It is inconvenient monthly dosing via IV. But the data looks pretty good, and you have a potential much better version of that drug, but pretty de-risked from Pfizer. The second program, JADE201, I am going again in reverse, is an anti-BAFF. Is this a much better version of the Novartis anti-BAFF that has positive Sjögren's data?
Is that correct? That is exactly right.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
